HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

prostaglandin endoperoxide receptor

Also Known As:
PG endoperoxide receptor; prostaglandin endoperoxide receptors; receptor, prostaglandin endoperoxide
Networked: 23 relevant articles (3 outcomes, 3 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Experts

1. Blanc-Guillemaud, Vanessa: 2 articles (03/2011 - 07/2010)
2. Castiglioni, Laura: 2 articles (03/2011 - 07/2010)
3. Gelosa, Paolo: 2 articles (03/2011 - 07/2010)
4. Lerond, Laurence: 2 articles (03/2011 - 07/2010)
5. Pignieri, Alice: 2 articles (03/2011 - 07/2010)
6. Sironi, Luigi: 2 articles (03/2011 - 07/2010)
7. Tremoli, Elena: 2 articles (03/2011 - 07/2010)
8. Capitao, Cristina: 1 article (04/2012)
9. Dean, Brian: 1 article (04/2012)
10. Tang, Bin: 1 article (04/2012)

Related Diseases

1. Thrombosis (Thrombus)
11/01/1988 - "To address whether this modulates the response to TXA2 synthase inhibition in the setting of thrombosis in vivo, we examined the interaction of a TXA2 synthase inhibitor (U63,557a) and a TXA2/prostaglandin endoperoxide receptor antagonist (L636,499) in a canine model of coronary thrombosis after electrically induced endothelial injury. "
08/01/1991 - "This study reveals 1) a differential efficacy of TXA2 synthase inhibition, singly or combined with TXA2/prostaglandin endoperoxide receptor antagonism, depending on the extent of the vessel wall lesion triggering thrombosis and the size of the thrombus required to obstruct the vascular lumen and 2) a significant synergism in preventing occlusive thrombosis of extensively damaged coronary arteries between strong TXA2 synthase inhibition and comparatively modest TXA2/prostaglandin endoperoxide receptor antagonism with ridogrel."
08/01/1991 - "Differential effects of thromboxane A2 synthase inhibition, singly or combined with thromboxane A2/prostaglandin endoperoxide receptor antagonism, on occlusive thrombosis elicited by endothelial cell injury or by deep vascular damage in canine coronary arteries."
02/01/1986 - "Therefore, reversal of coronary occlusion may reflect disaggregation of platelets and/or relaxation of vascular smooth muscle at the site of thrombus formation through specific antagonism of the thromboxane A2/prostaglandin endoperoxide receptor. "
04/25/1989 - "These results indicate that the thromboxane A2/prostaglandin endoperoxide receptor could play an important role in the pathogenesis of thrombosis and that ONO-3708 may have therapeutic advantages in preventing thrombosis."
2. Stroke (Strokes)
3. Coronary Artery Disease (Coronary Atherosclerosis)
4. Myocardial Infarction
5. Coronary Occlusion

Related Drugs and Biologics

1. Thromboxanes
2. ridogrel
3. terutroban
4. Thromboxane A2 (A2, Thromboxane)
5. Aspirin (Acetylsalicylic Acid)
6. Prostaglandin-Endoperoxide Synthases (Cyclooxygenase)
7. Ligases (Synthetase)
8. Heparin (Liquaemin)
9. Adenosine Diphosphate (ADP)
10. ONO 3708

Related Therapies and Procedures

1. Intravenous Administration